Mass drug administration

New York Blood Center Enterprises Grants Exclusive License to Big Eye Diagnostics for Diagnostic Biomarkers in River Blindness

Retrieved on: 
星期三, 十一月 1, 2023
National Institute of Allergy and Infectious Diseases, WHO, Onchocerciasis, MDA, Biomarker, Infection, NIAID, Research, Laboratory, Disease, World Health Organization, Risk, Mass drug administration, Partnership, Lindsley, Poverty, Onchocerca volvulus, NIH, Diagnosis, Bangladesh Technical Education Board, Pharmaceutical industry, Medical device

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) announced today it granted an exclusive commercial license to Big Eye Diagnostics for the rights to develop a diagnostic tool for onchocerciasis or river blindness.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) announced today it granted an exclusive commercial license to Big Eye Diagnostics for the rights to develop a diagnostic tool for onchocerciasis or river blindness.
  • River Blindness impacts 18 million individuals, with an additional 218 million at risk of contracting the disease.
  • Furthermore, the resulting solution could streamline deployment in the affected geographies, addressing a significant need in the fight against river blindness.
  • "This innovative work from NYBC and NIH provides the necessary foundation to improve diagnosis in a global effort to eliminate river blindness."

Emergence of Multidrug-Resistant Strains Steers Global Tuberculosis Therapeutics Market Towards $2.99 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
星期四, 七月 20, 2023
Infectious Diseases, Hospitals, Pharmaceutical, Health, Route of administration, Tuberculosis, Therapy, Prevalence, Antimalarial medication, Dosage form, TB, Linezolid, World Health Organization, COVID-19, Miliary tuberculosis, Active, USD, Market, BCG, Incidence, Mass drug administration, Guideline, Patient, Mortality, WHO, Death, Moxifloxacin, Pharmaceutical industry

The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030.

Key Points: 
  • The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030.
  • The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis.
  • The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021.
  • Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market.

Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease

Retrieved on: 
星期三, 三月 22, 2023
Software, Research, General Health, Pharmaceutical, Oncology, Data Management, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Tissue, Muscular Dystrophy Association, Pompe, Glycogen, Glycogen storage disease type II, Enzyme replacement therapy, Blood, HIV disease progression rates, Patient, Episcopal conference, MDA, Therapy, Mass drug administration, Conference, Biopsy, Pharmaceutical industry, Maze, PBMC

The data are being presented today, March 22, 2023, from 3:00-3:15 p.m. CT, during a late-breaking clinical session at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas.

Key Points: 
  • The data are being presented today, March 22, 2023, from 3:00-3:15 p.m. CT, during a late-breaking clinical session at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas.
  • The buildup of glycogen in skeletal, respiratory and cardiac muscle tissues is the primary driver of disease progression in patients with Pompe disease.
  • MZE001, a selective inhibitor of glycogen synthase 1 in muscle, is being developed to address this therapeutic gap.
  • Maze has developed a novel biomarker, peripheral blood mononuclear cell (PBMC) glycogen, as a surrogate for glycogen in skeletal muscle.

Orbis International Celebrates 23 Years of Achievements in Trachoma Elimination in Ethiopia this World Neglected Tropical Diseases Day

Retrieved on: 
星期四, 一月 27, 2022
People, COVID-19, Water, Severe cognitive impairment, Azithromycin, Neglected tropical diseases, Mass drug administration, WHO, Missionary, Federal Ministry of Health (Nigeria), MDA, Ophthalmology, SNNPR, Knowledge, Achievement, World NTD Day, Orbis International, Hospital, University, School, Government, Organization, Prevalence, Research, Scar, MD-10, Organic, NTD, Southern Nations, Nationalities, and Peoples' Region, Recurrence, Eye, Disease, Sustainable development, Pharmaceutical industry, Trachoma, Orbis, Health

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Ahead of World Neglected Tropical Diseases (NTD) Day, leading eye care nonprofit Orbis proudly celebrates 23 years of working to eliminate the blindness-causing infection trachoma in Ethiopia.

Key Points: 
  • NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Ahead of World Neglected Tropical Diseases (NTD) Day, leading eye care nonprofit Orbis proudly celebrates 23 years of working to eliminate the blindness-causing infection trachoma in Ethiopia.
  • Trachoma is highly contagious, but it is easily treatable with antibiotics if it is caught early.
  • Orbis ultimately administered more than 12.3 million doses of the antibiotic Azithromycin in these regions, where the burden of trachoma remains particularly high.
  • "This World NTD Day, Orbis is proud to join the WHO and more than 300 other organizations coming together to combat NTDs.

Global Malaria Markets, Epidemiology and Patient Flow Report 2020-2035 - Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Retrieved on: 
星期五, 五月 14, 2021
Health, Other Health, Infectious diseases, Medical specialties, Tropical diseases, Malaria, Malaria Atlas Project, Mass drug administration

b'The "Global Malaria Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Malaria Epidemiology and Patient Flow Analysis - 2021, provides Malaria epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Malaria Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Malaria Epidemiology and Patient Flow Analysis - 2021, provides Malaria epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Malaria patients, history of the disease at the population level (Malaria prevalence, Malaria incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Malaria patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Malaria market sizing, assessing market potential, and developing drug forecast models\nIdentify Malaria patients segments through age groups, gender, and disease sub-types\n'

Chloroquine Market | Increasing Prevalence of Malaria to Boost the Market Growth | Technavio

Retrieved on: 
星期六, 十月 10, 2020
Infectious diseases, Pharmaceutical, Health, Infectious diseases, Medical specialties, RTT, Clinical medicine, Chloroarenes, Quinolines, Tropical diseases, Chloroquine, Malaria, Mass drug administration, Antimalarial medication

Thus, the increasing prevalence of malaria will drive the growth of the chloroquine market.

Key Points: 
  • Thus, the increasing prevalence of malaria will drive the growth of the chloroquine market.
  • The high prevalence rate of malaria, increasing awareness about the treatment options for malaria, and strong funding by governments and private organizations to eradicate malaria are the main factors driving the growth of the chloroquine market in the malaria segment.
  • To help clients improve their market position, this chloroquine market forecast report provides a detailed analysis of the market leaders.
  • The growing demand across the world and increasing production of chloroquine by key vendors will boost the growth of the global chloroquine market during the forecast period.

Juntendo University Research: Malaria in Africa is Developing Resistance to Drugs

Retrieved on: 
星期一, 四月 23, 2018
Medicine, Clinical medicine, Health, Tropical diseases, Artemisinin, Malaria, Drug resistance, Mass drug administration, Center for Disease Dynamics, Economics & Policy

The emergence of drug resistance is one of the main threats in the global fight against malaria.

Key Points: 
  • The emergence of drug resistance is one of the main threats in the global fight against malaria.
  • Importantly, since 90% of malaria cases exist in Africa, the development of resistance to aremisinin-the major drug used to treat malaria-in this region would have profound consequences for global strategies to combat malaria.
  • The main reason why malaria incidence and deaths are decreasing is the deployment of combination therapies based on a drug called artemisinin.
  • However, parasites can develop resistance to artemisinin, as was reported starting in 2007-2008, and resistance is known to be spreading in Southeast Asia.